文献速递泌尿生殖与妇科肿瘤放疗

基因组分类器指导中危前列腺癌接受剂量递增图像引导放疗而不联合激素治疗

Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-08-29

本研究纳入121例接受剂量递增图像引导放疗(78 Gy/39次)而未联合雄激素剥夺治疗的中危前列腺癌患者,评估22特征基因组分类器(GC)的预后价值。结果显示GC评分较高与生化复发和转移相关,而NCCN风险亚组无此关联;GC预测5年生化失败AUC为0.78,NCCN+GC联合模型预测5年转移的AUC为0.89。作者认为需在前瞻性临床试验中评估GC。

要点

  • GC评分每增加10%,生化复发HR 1.36(95%CI 1.09-1.71,P=.007),转移HR 2.05(95%CI 1.24-4.24,P=.004)。
  • GC预测5年生化失败AUC为0.78(95%CI 0.59-0.91)。
  • NCCN+GC联合模型预测5年转移AUC为0.89,优于GC单独0.86和NCCN单独0.54。

核心结论

  • GC对仅接受剂量递增图像引导放疗的中危前列腺癌的疾病复发具有预测准确性。
  • 作者认为需在前瞻性临床试验中评估GC,以研究中危前列腺癌临床基因组定义亚组中ADT-RT的作用。

研究设计与样本

  • 研究纳入121例接受剂量递增图像引导放疗(78 Gy/39次)而未联合ADT的中危前列腺癌患者。
  • GC评分从诊断性活检肿瘤样本中得出。
  • 采用多变量分析,纳入NCCN亚分类和GC评分,评估生化失败(前列腺特异性抗原最低值+2 ng/mL)和转移发生。

主要发现

  • 按NCCN亚分类,33例(27.3%)为有利中危前列腺癌,87例(71.9%)为不利中危前列腺癌,1例无法分类。
  • GC评分在3例有利中危前列腺癌中为高,在60例不利中危前列腺癌中为低。
  • GC评分较高与生化复发相关(HR 1.36,95%CI 1.09-1.71,每增加10%,P=.007),NCCN风险亚组无此关联。
  • GC评分较高与转移相关(HR 2.05,95%CI 1.24-4.24,P=.004),NCCN风险亚组无此关联。
  • GC预测5年生化失败AUC为0.78(95%CI 0.59-0.91);NCCN+GC联合模型预测5年转移AUC为0.89,GC单独为0.86,NCCN单独为0.54。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为需在前瞻性临床试验中评估该GC,以研究ADT-RT在临床基因组定义的中危前列腺癌亚组中的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The National Comprehensive Cancer Network (NCCN) has recently endorsed the stratification of intermediate-risk prostate cancer (IR-PCa) into favorable and unfavorable subgroups and recommend the addition of androgen deprivation therapy (ADT) to radiation therapy (RT) for unfavorable IR-PCa. Recently, more accurate prognostication was demonstrated by integrating a 22-feature genomic classifier (GC) to the NCCN stratification system. Here, we test the utility of the GC to better identify patients with IR-PCa who are sufficiently treated by RT alone. METHODS AND MATERIALS: We identified a novel cohort comprising 121 patients with IR-PCa treated with dose-escalated image guided RT (78 Gy in 39 fractions) without ADT. GC scores were derived from tumors sampled in diagnostic biopsies. Multivariable analyses, including both NCCN subclassification and GC scores, were performed for biochemical failure (prostate-specific antigen nadir + 2 ng/mL) and metastasis occurrence. RESULTS: By NCCN subclassification, 33 (27.3%) and 87 (71.9%) of men were classified as having favorable and unfavorable IR-PCa, respectively (1 case unclassifiable). GC scores were high in 3 favorable IR-PCa and low in 60 unfavorable IR-PCa. Higher GC scores, but not NCCN risk subgroups, were associated with biochemical relapse (hazard ratio, 1.36; 95% confidence interval [CI], 1.09-1.71] per 10% increase; P = .007) and metastasis (hazard ratio, 2.05; 95% CI, 1.24-4.24; P = .004). GC predicted biochemical failure at 5 years (area under the curve, 0.78; 95% CI, 0.59-0.91), and the combinatorial NCCN + GC model significantly outperformed the NCCN alone model for predicting early-onset metastasis (area under the curve for 5-year metastasis of 0.89 vs 0.86 [GC alone] vs 0.54 [NCCN alone]). CONCLUSIONS: We demonstrated the accuracy of the GC for predicting disease recurrence in IR-PCa treated with dose-escalated image guided RT alone. Our findings highlight the need to evaluate this GC in a prospective clinical trial investigating the role of ADT-RT in clinicogenomic-defined IR-PCa subgroups.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Berlin A, Murgic J, Hosni A, et al. Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose-Escalated Image Guided Radiation Therapy Without Hormone Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 30170099. doi:10.1016/j.ijrobp.2018.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。